Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Lupin will conduct an Earnings Call for Q1 FY27 on August 07, 2026, at 4:30 PM IST. The call will discuss the company's financial results and provide an update on operations.
Jul 22 2026 18:49:17
Lupin Ltd - 500257 - Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Lupin's Board will meet on August 06, 2026, to consider and approve the standalone and consolidated financial results for the quarter ended June 30, 2026. This meeting is for the upcoming Q1 FY27 earnings.
Jul 22 2026 16:35:37
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Acquisition
Lupin Inc., a wholly-owned subsidiary, acquired an 82.2% equity stake in Kaveri Therapeutics, Inc. by licensing two oncology programs. This strategic move aims to advance the programs through global clinical trials and secure additional funding.
Jul 21 2026 07:13:06
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Lupin's Board recommended a final dividend of Rs.18 per share for FY26, representing 900% on a face value of Rs.2. The AGM is scheduled for August 4, 2026, and the record date for determining eligible shareholders for the dividend is July 17, 2026.
Jul 09 2026 19:18:17
Lupin Ltd - 500257 - Intimation Of Record Date For Payment Of Final Dividend.
Lupin has set July 17, 2026, as the Record Date for its final dividend of ₹18 per equity share for FY26. The dividend payment is subject to shareholder approval at the upcoming AGM.
Jul 08 2026 16:51:57
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Limited has been named among the World's Most Sustainable Companies by TIME and Statista, ranking 318th out of 750 global firms. This recognition acknowledges the company's strong ESG performance and commitment to sustainability.
Jul 06 2026 10:16:16
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin received an Establishment Inspection Report (EIR) from the U.S. FDA for its Somerset manufacturing facility, with a satisfactory Voluntary Action Indicated (VAI) classification. This outcome reflects the company's commitment to quality and compliance, which is crucial for its operations.
Jul 01 2026 21:55:38
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin received EMA approval for NaMuscla® to expand its pediatric indication to treat non-dystrophic myotonic disorders in children and adolescents. This approval also includes new 62mg and 83mg dosage strengths, in addition to the existing 167mg.
Jul 01 2026 16:47:31
Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lupin Limited received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Enzalutamide Tablets across multiple strengths. This approval allows Lupin to market a generic version of a key oncology drug.
Jun 26 2026 09:37:25
Read More